NASDAQ: ANEBAnebulo Pharmaceuticals Inc Stock
$1.21+0.03 (+2.54%)
Updated Apr 30, 2025
ANEB Price
$1.21
Fair Value Price
$0.12
Market Cap
$49.71M
52 Week Low
$0.80
52 Week High
$3.20
P/E
-4.32x
P/B
3.32x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$7.67M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.06
Operating Cash Flow
-$7M
Beta
0.52
Next Earnings
May 13, 2025
Ex-Dividend
N/A
Next Dividend
N/A
ANEB Overview
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, develops treatments for people suffering from acute cannabinoid intoxication and substance addiction. The Company's lead product candidate, ANEB-001, is a potent, small molecule cannabinoid receptor antagonist designed to address the unmet medical need for a specific antidote for cannabinoid overdose. The company was incorporated in 2020 and is based in Lakeway, TX.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ANEB's potential to beat the market
- ANEB doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
ANEB
RankedUnranked of 462
RankedUnranked of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $3.07 | A | |
| $8.24 | A | |
| $24.29 | A |
Be the first to know about important ANEB news, forecast changes, insider trades & much more!
ANEB News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ANEB scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ANEB ($1.21) is overvalued by 909.79% relative to our estimate of its Fair Value price of $0.12 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ANEB ($1.21) is not significantly undervalued (909.79%) relative to our estimate of its Fair Value price of $0.12 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ANEB is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ANEB due diligence checks available for Premium users.
Valuation
ANEB fair value
Fair Value of ANEB stock based on Discounted Cash Flow (DCF)
Price
$1.21
Fair Value
$0.12
Overvalued by
909.79%
ANEB ($1.21) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ANEB ($1.21) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ANEB is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ANEB price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-4.32x
Industry
-162.28x
Market
29.18x
ANEB price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
3.32x
Industry
4.45x
ANEB is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ANEB's financial health
Profit margin
Revenue
$0.0
Net Income
-$2.5M
Profit Margin
0%
ANEB's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$15.8M
Liabilities
$878.8k
Debt to equity
0.06
ANEB's short-term assets ($15.40M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ANEB's short-term assets ($15.40M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ANEB's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.4M
Investing
$0.0
Financing
$0.0
ANEB's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ANEB vs Biotech Stocks
Anebulo Pharmaceuticals Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.